SKVI SKINVISIBLE, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1085277 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY-111.2%
TTM EPS YoY—
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin-2,193.7%
Net margin-4,898.2%
FCF margin—
EBITDA margin-2,097.8%
Returns
ROE—
ROA-829.6%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets9,592.8%
Debt / equity—
Current ratio0.01x
Interest coverage-0.81x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-759.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20,000 | $20,000 | $20,000 | $279,296 | $663,426 |
| Cost of revenue | — | — | — | $4,808 | $3,300 |
| Gross profit | $20,000 | $20,000 | $20,000 | $274,488 | $660,126 |
| SG&A expense | $496,076 | $589,151 | $491,604 | $494,182 | $454,107 |
| Operating income | -$496,315 | -$589,589 | -$490,375 | -$238,432 | $188,080 |
| Interest expense | $572,249 | $669,438 | $1.89M | $1.16M | $1.21M |
| Net income | -$1.06M | -$565,654 | -$2.38M | -$1.22M | -$1.07M |
| EBITDA | -$476,076 | -$569,151 | -$471,604 | -$219,694 | $206,019 |
| EPS (diluted) | — | -0.11 | -0.52 | -0.27 | -0.24 |
| Weighted avg. shares (diluted) | — | 5.06M | 4.54M | 4.54M | 4.54M |
| Balance sheet | |||||
| Cash & equivalents | $2,620 | $10,336 | $888 | $81,378 | $66,037 |
| Receivables | $5,000 | $5,000 | $5,000 | $5,000 | — |
| Current assets | $27,531 | $42,028 | $35,460 | $109,946 | $74,244 |
| Intangibles | $100,036 | $116,189 | $127,409 | $136,847 | $153,055 |
| Total assets | $127,567 | $158,217 | $162,869 | $246,793 | $227,299 |
| Current liabilities | $5.02M | $3.66M | $3.51M | $3.64M | $3.06M |
| Total liabilities | $10.39M | $9.38M | $9.19M | $6.89M | $5.64M |
| Shareholders' equity | -$10.26M | -$9.22M | -$9.02M | -$6.64M | -$5.42M |
| Shares outstanding | 5.40M | 5.32M | 4.54M | 4.54M | 4.54M |
| Cash flow statement | |||||
| Operating cash flow | -$38,410 | -$69,834 | -$77,157 | $45,170 | $374,605 |
| Capital expenditure | $4,086 | $9,218 | — | — | — |
| Free cash flow | -$42,496 | -$79,052 | — | — | — |
| Investing cash flow | -$4,086 | -$9,218 | -$9,333 | -$2,530 | -$20,864 |
| Financing cash flow | $34,780 | $88,500 | $6,000 | -$27,299 | -$323,600 |
| Depreciation & amortization | $20,239 | $20,438 | $18,771 | $18,738 | $17,939 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.